Literature DB >> 17961036

Targeted drug therapy for meningiomas.

Andrew D Norden1, Jan Drappatz, Patrick Y Wen.   

Abstract

Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17961036     DOI： 10.3171/FOC-07/10/E12

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN： 1092-0684            Impact factor:   4.047


  18 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

2.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

3.  Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.

Authors:  Y Wu; K Lucia; M Lange; D Kuhlen; G K Stalla; U Renner
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

4.  Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.

Authors:  Mahlon D Johnson; Mary O'Connell; Webster Pilcher
Journal:  J Neurooncol       Date:  2010-07-02       Impact factor: 4.130

5.  Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Authors:  Vivek Subbiah; John Slopis; David S Hong; Leena M Ketonen; Jackson Hamilton; Ian E McCutcheon; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

6.  Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.

Authors:  Joseph R Linzey; Bernard L Marini; Amy Pasternak; Cory Smith; Zac Miklja; Lili Zhao; Chandan Kumar-Sinha; Alyssa Paul; Nicholas Harris; Patricia L Robertson; Lindsey M Hoffman; Arul Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  J Neurooncol       Date:  2017-12-12       Impact factor: 4.130

Review 7.  A review of malignant meningiomas: diagnosis, characteristics, and treatment.

Authors:  Simon Hanft; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

8.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

9.  Meningiomas.

Authors:  Sean Grimm; Jeffrey J Raizer
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

Review 10.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.